Novavax's R21/Matrix-M malaria vaccine, with 75% efficacy in seasonal areas. Affordable at $3 per dose, it outshines GSK's vaccine. Global rollout expected mid-2024.

Oxford researchers have developed a single-shot malaria vaccine using programmable microcapsules that release booster doses ...

The results of a clinical trial into a new malaria vaccine candidate (RH5.1/Matrix-MTM) show it is well-tolerated and offers effective protection against the blood-stage of the disease—the first ...

Novavax is a leading pharmaceutical company dedicated to creating protein-based vaccines for diseases like COVID-19 and malaria. Learn more about their innovative vaccine development process and ...

A malaria vaccine developed by members of the University of Oxford team behind the AstraZeneca COVID-19 jab has been hailed as a possible game-changer in the fight against the deadly parasitic ...

Novavax's fundamental prospects beyond COVID-19, such as its NanoFlu influenza vaccine and R21/Matrix-M malaria vaccine, raise questions about its long-term sustainability. solarseven/iStock via ...

Ivory Coast administered the first doses of the world’s second malaria vaccine this week, according to the vaccine’s manufacturers, marking the latest development in a decades-long effort to ...

Trials have shown it to be 79% effective at preventing the disease in young people, and its production capacity and low price give it a "huge advantage" over the only other malaria vaccine, RTS,S ...

The malaria vaccine needed this sign-off, and since the European agency, a stringent regulator, had approved it, GSK and PATH assumed the W.H.O. would do so swiftly, too.